Trilaciclib NEW
| Price | $89 | $579 | $786 |
| Package | 5mg | 50mg | 100mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: Trilaciclib | CAS No.: 1374743-00-6 |
| Purity: 99.62% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | Trilaciclib |
| Description | Trilaciclib is a short-acting, orally effective CDK4/6 inhibitor with IC?? values of 1 nM and 4 nM respectively. It transiently and reversibly induces G1 cell cycle arrest, mitigates chemotherapy-induced myelosuppression, and enhances antitumour immunity, making it applicable across multiple cancers. |
| In vitro | Methods: HS68 cells were treated with Trilaciclib (10-3000nM, 24 hours), fixed and stained with propidium iodide and RNAse A, then analyzed using a Cyan ADP Analyzer. Results: After 24 hours of treatment with 300 nM trilaciclib, the proportion of HS68 cells in the G1 phase reached as high as 98%.[1] |
| In vivo | Method: FVB/N mice were orally administered Trilaciclib (50, 100, 150 mg/kg, single dose), followed by EdU injection to measure the proliferation of bone marrow Lineage-negative cells. Results: Trilaciclib exhibited a dose-dependent effect, effectively suppressing the proliferation of bone marrow HSPCs. [1] |
| Storage | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 4.5 mg/mL (10.08 mM) |
| Keywords | Trilaciclib | CDK6 | CDK4 |
| Inhibitors Related | Ribociclib | (E)-β-Farnesene | Amantadine | 2-Chloropyrazine | Kojic acid | Abemaciclib | 2,4,6-Trihydroxybenzoic acid | Sodium citrate monobasic | Palbociclib | Abemaciclib methanesulfonate | Sodium Oxamate | Dinaciclib |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Approved Drug Library | Kinase Inhibitor Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
Moxin Chemicals
|
2025-12-16 | |||
| $263.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-08-22 | |
| $50.00 |
Anhui Ruihan Technology Co., Ltd
|
2023-08-22 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY